5 takeaways from 2015 TAVR benchmarks

By Marissa Schwartz, Megan Tooley, and Brian Contos

TAVR has been approved in the U.S. for nearly five years, but excitement over this ever-transforming technology only continues to grow. With positive results from recent trials of intermediate-risk patients, low-risk patient trials underway, and continued emergence of next-generation devices, the TAVR market is poised to keep growing.

To assess how the TAVR market has evolved in recent years, the Cardiovascular Roundtable has updated our benchmarks with the latest Medicare Provider Analysis and Review (MEDPAR) data set for fiscal year (FY) 2015. This includes all Medicare TAVR cases performed between October 1, 2014 and September 31, 2015.

Read on to learn how the TAVR market and practice pattern changes stacked up in FY 2015.

This is a preview of restricted content.

Full access to this content is reserved for Cardiovascular Roundtable members. Log in now or learn more about Cardiovascular Roundtable.

Next, Check Out

Is the TAVR halo effect real? Our analysis says yes.

More

Join the discussion

Please log in to comment.
Close

Forgot your password?


Not an Advisory Board Member? Click here to register

Close

Members please Log In

LOG IN

Forgot your password?


Not an Advisory Board Member? Click here to register